Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
RG7388
Description:
RG7388 is a small-molecule anticancer drug that selectively inhibits MDM2, disrupting its interaction with the tumor suppressor protein p53.
Primary topic:
Cancer-related Molecular Pathways (42%)
Related topics:
Cancer-related Molecular Pathways (42%),
Glioma Diagnosis and Treatment (11%),
Neuroblastoma Research and Treatments (9%)
OpenAlex ID:
keywords/rg7388
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
2013
·
Qingjie Ding
, Zhuming Zhang
, et al.
·
Journal of Medicinal Chemistry
·
638
MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)
2019
·
Arushi Khurana
, Danielle A Shafer
·
OncoTargets and Therapy
·
119
PDF
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
2020
·
Yuan Fang
, Guochao Liao
, et al.
·
Acta Pharmaceutica Sinica B
·
116
PDF
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
2017
·
Audrey Laroche-Clary
, Vanessa Chaire
, et al.
·
Journal of Hematology & Oncology
·
114
PDF
Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development
2013
·
Zhuming Zhang
, Xin-Jie Chu
, et al.
·
ACS Medicinal Chemistry Letters
·
97
Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts
2016
·
B. Reis
, L. Jukofsky
, et al.
·
Haematologica
·
96
The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma
2015
·
A Lakoma
, E Barbieri
, et al.
·
Cell Death Discovery
·
83
PDF
Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma
2015
·
Lindi Chen
, Raphaël F. Rousseau
, et al.
·
Oncotarget
·
82
PDF
Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts)
2014
·
Karen Yee
, Giovanni Martinelli
, et al.
·
Blood
·
80
Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
2018
·
Lukasz Skalniak
, Justyna Kocik
, et al.
·
Cancers
·
78
PDF
Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib
2018
·
Anne Berberich
, Tobias Kessler
, et al.
·
Clinical Cancer Research
·
77
PDF
Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells
2018
·
Umamaheswari Natarajan
, Thiagarajan Venkatesan
, et al.
·
Cells
·
76
PDF
Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer
2016
·
Maryam Zanjirband
, Richard J. Edmondson
, et al.
·
Oncotarget
·
68
PDF
Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
2014
·
Brian Higgins
, Kelli Glenn
, et al.
·
Clinical Cancer Research
·
67
PDF
Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma
2017
·
Chiao-En Wu
, Arman Esfandiari
, et al.
·
British Journal of Cancer
·
65
PDF
Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy
2014
·
Zhuming Zhang
, Qingjie Ding
, et al.
·
Bioorganic & Medicinal Chemistry
·
64
Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.
2014
·
Lillian L. Siu
, Antoine Italiano
, et al.
·
Journal of Clinical Oncology
·
64
Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner
2016
·
Arman Esfandiari
, Thomas A. Hawthorne
, et al.
·
Molecular Cancer Therapeutics
·
51
Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non–Small Cell Lung Cancer Xenograft Models
2015
·
Josephine Hai
, Shingo Sakashita
, et al.
·
Journal of Thoracic Oncology
·
47
Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
2017
·
Maryam Zanjirband
, Nicola Curtin
, et al.
·
Oncotarget
·
45
Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma
2014
·
L Chen
, Y Zhao
, et al.
·
British Journal of Cancer
·
45
PDF
ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma
2018
·
Chiao-En Wu
, Tsin Shue Koay
, et al.
·
Cancers
·
40
PDF
MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas
2017
·
Audrey Laroche
, Vanessa Chaire
, et al.
·
Oncotarget
·
38
PDF
MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma
2019
·
Xiaoqin Fan
, Yujie Wang
, et al.
·
Cancer Biology & Therapy
·
36
PDF
Structure-Based Discovery of MDM2/4 Dual Inhibitors that Exert Antitumor Activities against MDM4-Overexpressing Cancer Cells
2022
·
Shiyan Zhang
, Ziqin Yan
, et al.
·
Journal of Medicinal Chemistry
·
30
Show more works
View as search
Works count:
180
Citation count:
2,813
Year
Topic
Type